|
|||||
|
|
Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR,and plasma lipids in mouse and rhesus monkey |
|
| Affiliation: | 2. Genetics and Pharmacogenomics, Merck & Co. Inc., Boston, MA;4. Sirna Therapeutics Merck & Co. Inc., San Francisco, CA;11. Biostatistics, Merck & Co. Inc., Rahway, NJ;8. RNA Therapeutics, Merck & Co. Inc., West Point, PA |
| Abstract: | |
| Keywords: | lipid and lipoprotein metabolism metabolic disease lipids/liver animal models low density lipoprotein drug therapy cholesterol SREBP cleavage-activating protein cardiometabolic disease dyslipidemia small interfering ribonucleic acid proprotein convertase subtilisin kexin type 9 |
| 本文献已被 ScienceDirect 等数据库收录！ | |